文献速递糖尿病肥胖与代谢综合征

基于血液的肝纤维化标志物在心血管风险分层中的增量价值

Incremental Value of Blood-Based Markers of Liver Fibrosis in Cardiovascular Risk Stratification.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

在雅典心血管代谢队列1692例连续纳入的个体中,评估FIB-4、NFS和BARD评分与亚临床动脉损伤指标及主要不良心血管事件(MACE)的关联。FIB-4与多种血管损伤标志物、冠心病存在及MACE风险独立相关,且其关联由颈动脉最大壁厚而非脉搏波传导速度介导。FIB-4在既定心血管风险评分基础上提供增量预测价值。

要点

  • FIB-4是与多种血管损伤标志物、冠心病存在及MACE风险独立且一致相关的肝纤维化无创检测。
  • FIB-4>2.67与MACE风险增加相关(OR 2.00,95%CI 1.12-3.55),ΔAUC为0.014(95%CI 0.002-0.026)。
  • FIB-4(>3.25)与全因死亡率独立且增量相关(校正P<0.05)。

核心结论

  • 在心血管代谢特征多样的人群中,肝纤维化无创检测与心血管疾病结局的增量关联由动脉粥样硬化负荷而非动脉僵硬介导。
  • FIB-4与所有研究终点均显示一致关联,这些发现为FIB-4在心血管疾病预防中的临床应用提供了机制见解和支持。

研究设计与样本

  • 研究分析了来自雅典心血管代谢队列的连续招募个体(n=1692),包括有或无临床明显冠状动脉疾病(CAD)者。
  • 评估了纤维化-4指数(FIB-4)、NAFLD纤维化评分(NFS)和BARD评分与亚临床动脉损伤指标及主要不良心血管事件(MACE)复合终点的直接和间接关联。
  • MACE复合终点包括心源性死亡、急性心肌梗死或冠状动脉血运重建,中位随访39个月。

主要发现

  • FIB-4是唯一与多种血管损伤标志物一致相关的肝纤维化无创检测,无论是否存在CAD,且在校正传统危险因素、胰岛素抵抗替代指标或肥胖后均如此(校正P<0.05)。
  • FIB-4与CAD存在独立相关(校正OR 6.55;95%CI 3.48-12.3;P<0.001)。
  • FIB-4>2.67与MACE风险增加增量相关(OR 2.00,95%CI 1.12-3.55;ΔAUC 0.014,95%CI 0.002-0.026)。
  • 这些关联由颈动脉最大壁厚(maxWT)而非脉搏波传导速度(PWV)介导。
  • 仅FIB-4(>3.25)与全因死亡率独立且增量相关(校正P<0.05)。

关键数值与推荐

  • FIB-4>2.67与MACE风险增加相关:OR 2.00(95%CI 1.12-3.55),ΔAUC 0.014(95%CI 0.002-0.026)。
  • FIB-4与CAD存在独立相关:校正OR 6.55(95%CI 3.48-12.3),P<0.001。
  • FIB-4>3.25与全因死亡率独立且增量相关(校正P<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Nonalcoholic fatty liver disease (NAFLD) with advanced liver fibrosis is associated with cardiovascular disease (CVD). OBJECTIVE: This work aimed to examine if markers of vascular injury mediate the link between liver fibrosis noninvasive tests (LFNITs) and CVD events, and to compare the incremental predictive value of LFNITs over established CVD risk scores. METHODS: Consecutively recruited individuals (n = 1692) with or without clinically overt coronary artery disease (CAD) from the Athens Cardiometabolic Cohort, were analyzed. Fibrosis-4 index (FIB-4), NAFLD Fibrosis score (NFS), and BARD score were evaluated for direct and indirect associations with indices of subclinical arterial injury including carotid maximal wall thickness (maxWT) and pulse wave velocity (PWV) and with a composite of major adverse cardiovascular events (MACE) that consisted of cardiac death, acute myocardial infarction, or coronary revascularization (39-month median follow-up). RESULTS: FIB-4 was the only LFNIT that was consistently associated with multiple markers of vascular injury, irrespective of CAD presence and after controlling for traditional risk factors, surrogates of insulin resistance, or obesity (adjusted P < .05 for all). FIB-4 was also independently associated with CAD presence (adjusted odds ratio [OR] 6.55; 3.48-12.3; P < .001). Increased FIB-4 greater than 2.67 was incrementally associated with an increased risk for MACE (OR [95% CI] 2.00 [1.12-3.55], ΔAUC [95% CI] 0.014 [0.002-0.026]). These associations were mediated by maxWT rather than PWV. Only FIB-4 (>3.25) was independently and incrementally associated with all-cause mortality (adjusted P < 0.05). CONCLUSION: In a cardiometabolically diverse population, the incremental associations of LFNITs with CVD outcomes were mediated by atherosclerotic burden rather than arterial stiffening. FIB-4 consistently demonstrated associations with all study end points. These findings provide mechanistic insights and support the clinical applicability of FIB-4 in CVD prevention.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Georgiopoulos G, Athanasopoulos S, Mavraganis G, et al. Incremental Value of Blood-Based Markers of Liver Fibrosis in Cardiovascular Risk Stratification. J Clin Endocrinol Metab. 2025. PMID: 39257198. doi:10.1210/clinem/dgae619

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。